secwatch.observer — SEC 8-K summary
======================================

Issuer:     Finch Therapeutics Group, Inc. (FNCHQ)
CIK:        0001733257
Form:       8-K
Filed at:   2021-09-08T23:59:59+00:00
Accession:  0001564590-21-047253
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Finch Therapeutics appoints Marc Blaustein as COO effective Sept 8
------------------------------------------------------------------

- Marc Blaustein appointed COO, effective September 8, 2021.
- Base salary of $400,000; target bonus of 40% of base salary; options for 150,000 shares vesting over 4 years.
- Blaustein brings 20+ years biopharma experience, including roles at Dyax, Alkermes, and as CEO of NED Biosystems.
- CEO Mark Smith says Blaustein's operational expertise will be valuable as Finch enters next phase of growth.
- Severance includes 9 months salary (non-CIC) or 12 months salary (CIC) plus equity acceleration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733257/000156459021047253/0001564590-21-047253-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733257/000156459021047253/fnch-8k_20210908.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-047253

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer